Neuphoria Therapeutics
NEUP
12 hedge funds and large institutions have $1.74M invested in Neuphoria Therapeutics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 0 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
43% more capital invested
Capital invested by funds: $1.22M → $1.74M (+$519K)
33% more funds holding
Funds holding: 9 → 12 (+3)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.11M |
| 2 |
TSS
Two Sigma Securities
New York
|
+$23.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$22.7K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$9.93K |
| 5 |
LAM
Lewis Asset Management
Lafayette,
California
|
+$7.26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$195K |
| 2 |
Two Sigma Investments
New York
|
-$642 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $941K | +$1.11M | +102,230 | New |
|
|
LCM
2
Lynx1 Capital Management
San Juan,
Puerto Rico
| $460K | -$195K | -17,899 | -26% |
|
3
Point72 Asset Management
Stamford,
Connecticut
| $242K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $26.8K | +$22.7K | +2,080 | +251% |
|
|
TSS
5
Two Sigma Securities
New York
| $20K | +$23.6K | +2,170 | New |
|
|
LAM
6
Lewis Asset Management
Lafayette,
California
| $17.6K | +$7.26K | +667 | +53% |
|
|
7
Two Sigma Investments
New York
| $12.6K | -$642 | -59 | -4% |
|
|
XT
8
XTX Topco
George Town,
Cayman Islands
| $8.39K | +$9.93K | +912 | New |
|
|
BPA
9
Beacon Pointe Advisors
Newport Beach,
California
| $7.67K | – | – | – |
|
10
RhumbLine Advisers
Boston,
Massachusetts
| $1.68K | +$806 | +74 | +68% |
|
11
Morgan Stanley
New York
| $609 | +$632 | +58 | +725% |
|
|
APC
12
Aspire Private Capital
Cornelius,
North Carolina
| $153 | – | – | – |
|
13
JP Morgan Chase
New York
| $1 | – | – | – |
|
NEUP Hedge Fund Activity: Q2 2024 in Review
12 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q2 2024, worth a combined $1.74M — up 43% from $1.22M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NEUP positions and 0 closed out — a net gain of 3 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.11M. The largest seller was Lynx1 Capital Management, cutting an estimated $195K.
- 12 institutional investors held Neuphoria Therapeutics (NEUP) as of Q2 2024, up from 9 in Q1 2024.
- Funds reported $1.74M of Neuphoria Therapeutics stock for Q2 2024, up 43% quarter-over-quarter.
- 3 funds opened new Neuphoria Therapeutics positions in Q2 2024 and 0 closed out, a net change of +3 holders.
- The largest Neuphoria Therapeutics buyer in Q2 2024 was Armistice Capital, an estimated $1.11M added.
- The largest Neuphoria Therapeutics seller in Q2 2024 was Lynx1 Capital Management, an estimated $195K sold.
Based on aggregated 13F filings for Q2 2024.